Dublin, Jan. 17, 2022 (GLOBE NEWSWIRE) — The "Pulmonary Drug Delivery Systems Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
The pulmonary drug delivery systems market is projected to grow at a CAGR of 4.83% to reach US$56.942 billion by 2026, from US$40.929 billion in 2019.
The increasing prevalence of the chronic respiratory disease worldwide will drive the market growth of the pulmonary drug delivery systems market during the forecast period. According to the World Health Organization, more than 1 billion people suffer from either acute or chronic respiratory conditions. Around 4 million people die prematurely from chronic respiratory diseases. In addition, nearly 235 million people suffer from asthma in the world and over 80% of the deaths due to Asthma occur in low and middle-income countries. The increasing incidence of such diseases will support the market growth as more patients will require the pulmonary drug delivery system for their treatment.
Increasing geriatric population
Moreover, the rapidly growing geriatric population worldwide will contribute to the market growth as they are more prone to chronic respiratory diseases such as bronchitis, tuberculosis, and chronic obstructive pulmonary disease, etc. which will surge the demand for pulmonary drug delivery systems in the market. According to the United Nations, in 2019, the geriatric population was 703 million persons, nationwide. The number of older persons is projected to double to 1.5 billion in 2050.
Health awareness
Furthermore, the growing health awareness and increasing investment in the healthcare and drug delivery industry by both public and private players are also expected to further fuel up the growth of the market. Also, the initiative taken by the governing bodies of various countries is increasing health awareness among the people. For instance, the National Asthma Control Program (NACP) by CDS, provides funds for educating asthma-affected patients. Such initiatives will encourage more patients to adopt pulmonary drug delivery systems for their treatment which will further strengthen the market growth during the forecast period.
Market Segmentation
By product, the dry powder inhalers (DPIs) segment is projected to hold a significant market share owing to the advantages such as short administration & preparation time, ease of use, and fewer irritant effects associated with the use of these inhalers. Geographically, North America holds a significant market share due to the increasing prevalence of chronic respiratory diseases, early adoption of the pulmonary drug delivery systems, and the surge in healthcare spending in the region. Asia Pacific will be the fastest-growing market region owing to the rapidly growing geriatric population, increasing adoption of an unhealthy lifestyle, and rising urbanization in the region.
Growth Factors
Increase in the geriatric population
The increase in the geriatric population across the globe is expected to drive the market growth of pulmonary drug delivery systems. According to COPD, about 1 in 7 older adults suffers from some of the other forms of lung disease. The geriatric population is more prone to chronic respiratory diseases as compared to the younger population which will increase the demand for pulmonary drug delivery systems in the market during the forecast period.
Restraints
Lack of awareness
The pulmonary drug delivery system is a relatively new system due to which not many patients are aware of the advantages of using this system which may restrain the market growth during the forecast period. The patients, especially in the developing countries are unaware of the existence of this system due to which the demand for it is low in these countries. However, with the increasing awareness by both the public and private players the patients are expected to become aware and adopt these systems.
Segmentation:
By Product
Metered-dose inhalers (MDIs)
Dry Powder Inhalers (DPIs)
Soft mist inhaler (SMI)
Nebulizers
By Distribution Channel
Offline
Online
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
UK
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
Japan
China
India
Indonesia
Taiwan
Thailand
Companies Mentioned
Philips Respironics
GlaxoSmithKline PLC
Boehringer Ingelheim GmbH
Teva Pharmaceutical Industries Ltd.
3M Healthcare
PARI GmbH
F. Hoffmann-La Roche AG
Gilbert Technologies
AstraZeneca PLC
For more information about this report visit https://www.researchandmarkets.com/r/hu7zbd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
In particular, Abbott Laboratories (NYSE: ABT) makes BinaxNOW kits, which are the most popular rapid coronavirus antigen diagnostic test in the U.S. Are things different this time as a result of the omicron variant wave, or is Abbott on track to disappoint? Coronavirus rapid testing revenue has been all over the place, appearing to ebb and flow based on the public's perceptions about where the pandemic is headed.
On 20th January, a U.S subcommittee hearing on cryptos is scheduled, the outcome of which could have significant ramifications for Bitcoin miners…
Saudi Arabia’s planned purchase of Polish refining assets is set to put OPEC's top producer in charge of two thirds of Poland's oil supply, eroding previously dominant supplier Russia's leverage as it grapples with regional tension. Poland has a long history of seeking to reduce its dependence on Russian energy imports through deals with alternative suppliers and its determination has grown as relations have worsened. The mood between Poland and Russia had already darkened over oil supplies early in 2021 when Poland had to cut its oil purchases from Russia because of a price row between Russia's Rosneft and Poland's PKN Orlen.
(Bloomberg) — Saudi Arabia’s energy minister said it’s not the time to talk about oil prices.Most Read from BloombergOne of the World’s Wealthiest Oil Exporters Is Becoming UnlivableDeadly Strikes on UAE Upset Efforts to Ease Gulf FrictionsDjokovic Loses Shot at Tennis History as Australia Deports StarChina Cuts Interest Rate as Growth Risks Worsen With OmicronPutin’s Troops Wouldn’t Get Cheers in This Once Pro-Russia City“Now is not the time,” Abdulaziz bin Salman said at a renewable-energy ev
Moderna is looking to expand the use of mRNA drug technology to other vaccines. So far, investors haven't been impressed by progress on a flu shot.
(Bloomberg) — The world’s biggest independent oil trader said crude prices, already up more than 10% this year, could rise even further because of tight supplies.Most Read from BloombergOne of the World’s Wealthiest Oil Exporters Is Becoming UnlivableDjokovic Loses Shot at Tennis History as Australia Deports StarChina Cuts Interest Rate as Growth Risks Worsen With OmicronIran-Backed Houthis Claim Drone Strikes on UAE, Three DiePutin’s Troops Wouldn’t Get Cheers in This Once Pro-Russia City“Thes
The oil market hasn't always been kind to dividend investors. The sector has often had to slash or suspend dividend payments during oil price downturns, which have happened twice this decade. Instead of setting a high base payout, some are setting lower quarterly payments and supplementing with variable or special dividends when oil prices are higher.
Recently, AstraZeneca (NASDAQ: AZN) announced what could be very positive regulatory news for one of its rare disease drugs. The pharma stock informed shareholders that the U.S. Food and Drug Administration (FDA) accepted the regulatory submission under priority review for Ultomiris to treat adults diagnosed with the rare condition called generalized myasthenia gravis (gMG). According to AstraZeneca, gMG is an autoimmune disease, which damages the connection point between the nerve cells and the muscles that they control.
Surge Energy Inc. ("Surge" or the "Company") (TSX: SGY) is pleased to announce its 2022 budget guidance, as approved by the Company's Board of Directors, an update on Surge's anticipated reinstatement of Management's shareholder returns focused business model, and an operations update.
Pavia.io has become the first metaverse project to launch on the Cardano blockchain, with ADA soaring by 11% since the announcement.
Many workers are not confident that Social Security will be around during their retirement. Here’s what you need to know about its future.
LONDON (Reuters) -Oil prices rose modestly on Monday as investor bets that global supply will remain tight amid restraint by major producers were partially offset by a rise in Libyan output. Trade was subdued due to the U.S. holiday honoring Martin Luther King Jr. "The bullish sentiment is continuing as (producer group) OPEC+ is not providing enough supply to meet strong global demand," said Fujitomi Securities analyst Toshitaka Tazawa.
Walmart has filed several trademark applications, one of which is “Verse to Store,” “Verse to Curb” and “Verse to Home” for the shopping category.
Investing billions in stores, upping wages, digital and other areas before the pandemic and its multicategory offering helped Target flourish through the global health crisis.
by Susan Moore
Alibaba is the world’s largest online and mobile commerce company as measured by gross merchandise volume (CNY 7.5 trillion for the fiscal year ended March 2021). It operates China’s online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). Alibaba's China commerce retail division accounted for 63% of revenue in the September 2021 quarter. Additional revenue sources include China commerce wholesale (2%), international retail/wholesale marketplaces (5%/2%), cloud computing (10%), digital media and entertainment platforms (4%), Cainiao logistics services (5%), and innovation initiatives/other (1%).
An infectious disease expert weighs in on when to use these tests at home.
U.S. Sen. Rand Paul hit back at YouTube "censors" on Saturday after the Centers for Disease Control and Prevention acknowledged that cloth masks do not work as well against the coronavirus as N95 makes.
In this article, we will be looking at some 3D printing stocks bought by hedge funds. If you want to skip our comprehensive analysis on the 3D printing industry, you can go directly to the 5 3D Printing Stocks Hedge Funds Like. 3D Printing or Additive Manufacturing is the process of creating a three-dimensional object through […]
Tesla has just signed a deal with an Austrailian company to source graphite from its mines in Mozambique.
